StreetAlpha.app
Home › Stocks › AURA

Aura Biosciences, Inc. (AURA)

Healthcare
$7.15
▼ −0.97%
LAST CLOSE · NOV 17

Aura Biosciences develops bel sar, an experimental cancer drug for eye and bladder tumors that is still in clinical trials. It last closed at $7.15 on Nov 17, down 0.97% on the day. In the past 30 days there were 1 dark pool print totaling $261K, the largest $261K.

AI Auto Pilots
Is AURA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$136.9M
EPS (diluted)
−$1.59
Free cash flow
−$109.7M
Valuation
Market cap
$744.1M
104.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.7M
At Sep 30
Shareholder equity
$287.4M
Shares outstanding
104.1M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$35.3M−$35.3MFY2021FY2022: −$58.8M−$58.8MFY2022FY2023: −$76.4M−$76.4MFY2023FY2024: −$86.9M−$86.9MFY2024FY2025: −$106.2M−$106.2MFY2025

From AURA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated AURA in the past 90 days.
Average 12-month target
No price targets on AURA in the past 90 days.
Latest rating changes
HC Wainwright & Co.Maintained
Aug 11Buy$18
Evercore ISI GroupReinstated
Nov 26Buy$13
DateFirmActionRatingPrice target
Aug 11HC Wainwright & Co.MaintainedBuy$18
Nov 26Evercore ISI GroupReinstatedBuy$13
Loading…

Technical Analysis

AURA · as of the Nov 17 close · updated after every close
Uptrend

The stock is 6% above its 20 day and 9% above its 50 day average. It is 5% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 57). The nearest support is the swing low (Aug 12) at $7.07, and the nearest resistance the Pivot R1 at $7.30.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 5.4%/day
Key levels
$9.5452 week high+33.4%
$7.31Swing high (Jul 27)+2.2%
$7.30Pivot R1+2.1%
$7.15Pivot+0.0%
$7.15Last close
$7.07Swing low (Aug 12)−1.1%
$7.00Pivot S1−2.1%
$6.94100 day average−2.9%
$6.80200 day average−4.9%
$6.6920 day average−6.4%
$6.5350 day average−8.7%
$4.7352 week low−33.8%
Indicators
RSI (14)57.41Middle of its rangeNeutral
MACD0.22Above its signal lineBullish
Stochastic62.0Middle of its rangeNeutral
ADX (14)20.3Weak trend
Williams %R-38.5Oversold below −80, overbought above −20Neutral
CCI (20)71.7Oversold below −100, overbought above 100Neutral
Rate of change+14.6%Change over 10 sessionsBullish
ATR (14)$0.38Typical daily range, 5.4% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for AURA

What happened before

See how AURA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AURA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AURA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in AURA in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$261K
Largest print
$261K
Loading…

AURA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲86 buying vs 53 selling
  • ▲Held by funds +3.5 pts
  • ▲Funds holding +8
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding154146+5.5%
In funds' top 10220.0%
Held by funds98.0%94.5%+3.5 pts
New / increased25 / 6136 / 58−8.5%
Reduced / sold out35 / 1827 / 15+26.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AURA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AURA is in one of them and how their past AURA trades turned out.

AURA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AURA in an article yet. Here's the latest on the wider market.

About Aura Biosciences

Aura Biosciences is a biotechnology company developing drugs to treat solid tumors while aiming to preserve organ function. Its lead candidate, bel sar, is in later stage clinical trials for early choroidal melanoma, a rare eye cancer, and is also being tested in other eye cancers and in bladder cancer. Bel sar is built from modified human papilloma virus proteins linked to molecules that are activated by light, and it has not yet been approved for sale. The company is based in Boston, Massachusetts, and its intended patients are adults with these cancers.

Headquarters
Boston, MA